Build status - In Progress
Search filters
Filters
Clear All

Phase

  • 5
  • 30
  • 1
  • 7
  • 1
  • 5
  • 49
  • 27
  • 49

Found 49 Solid Tumors trials

A listing of Solid Tumors medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

UPCC 06922: A First-in-Human Open-label Dose-escalation Trial with Expansion Cohorts to Evaluate Safety and Anti-tumor Activity of GEN1042 in Subjects with Malignant Solid Tumors

99 years or below
All genders
Phase 1
Please refer to Section 3 of the full protocol (Objectives and Endpoints) Please refer to Section 3 of the full protocol (Objectives and Endpoints) Please refer to Section 3 of the full protocol (Objectives and Endpoints)
Learn More

UPCC 18920: A Phase 1 First in Human Study of Adenovirally Transduced Autologous Macrophages Engineered to Contain an Anti-HER2 Chimeric Antigen Receptor in Subjects with HER2 Overexpressing Solid Tumors

99 years or below
All genders
Phase 1
This study tests the effects of an investigational product, CT-0508, and to see how safe CT-0508 is for patients with advanced cancer. One purpose of this study is to see if CT-0508 cells can be made and then safely given back to patients with HER2-positive cancers. A second purpose is …
Learn More

UPCC 26921: A Phase 1a/1b Open-label Dose-Escalation and Expansion Study of TPST-1495 as a Single Agent and in Combination with Pembrolizumab in Subjects with Solid Tumors

99 years or below
All genders
Phase 1
Please refer to Section 4 of the full protocol (Study Objectives and Endpoints) Please refer to Section 4 of the full protocol (Study Objectives and Endpoints) Please refer to Section 4 of the full protocol (Study Objectives and Endpoints)
Learn More

A Phase 1 Open-Label Multi-Center First in Human Study of TnMUC1-Targeted Genetically-Modified Chimeric Antigen Receptor T Cells in Patients with Advanced TnMUC1-Positive Solid Tumors and Multiple Myeloma

99 years or below
All genders
Phase 1
Multi-center, open-label, first in human (FIH) Phase 1 study of the safety, tolerability, feasibility, and preliminary efficacy of the administration of genetically modified autologous T cells (CART-TnMUC1 cells) engineered to express a chimeric antigen receptor (CAR) capable of recognizing the tumor antigen, TnMUC1 and activating the T cell (CARTTnMUC1 cells). …
Learn More

UPCC 38922: A Phase I Multicenter Open-label First-in Human Dose Escalation and Expansion Study of AZD9592 as Monotherapy and in Combination with Anti-cancer Agents in Patients with Advanced Solid Tumors

99 years or below
All genders
Phase 1
Please refer to Protocol D9350C00001, Section 3 (Objectives and Endpoints) Please refer to Protocol D9350C00001, Section 3 (Objectives and Endpoints) Please refer to Protocol D9350C00001, Section 3 (Objectives and Endpoints)
Learn More

UPCC 29922: First-in-human open-label multicenter Phase I/IIa dose escalation trial with expansion cohorts to evaluate safety and preliminary efficacy of BNT142 in patients with CLDN6-positive advanced solid tumors

99 years or below
All genders
Phase 1
Please refer to Protocol BNT142-01, section 1.1 Trial synopsis, Objectives and endpoints. Please refer to Protocol BNT142-01, section 1.1 Trial synopsis, Objectives and endpoints. Please refer to Protocol BNT142-01, section 1.1 Trial synopsis, Secondary objectives.
Learn More

UPCC 52422: A Phase 1 Multicenter Open-Label Dose-Escalation and Expansion Study to Evaluate the Safety Tolerability Pharmacokinetics Pharmacodynamics and Clinical Activity of Intravenously Administered KT-333 in Adult Patients with Relapsed or Refractory Lymphomas Large Granular Lymphocytic Leukemia and Solid Tumors

99 years or below
All genders
Phase 1
Please refer to Protocol Section 2 (Objectives and Endpoints) Please refer to Protocol Section 2 (Objectives and Endpoints) Please refer to Protocol Section 2 (Objectives and Endpoints)
Learn More

UPCC 22918: A Phase 1 Study Exploring the Safety Tolerability Pharmacokinetics and Pharmacodynamics of INCB086550 in Participants with Advanced Solid Tumors

99 years or below
All genders
Phase 1
The purpose of this Study is to test the safety and tolerability of the INCB086550 and to find out what effects, if any, the INCB086550 has on people and their cancer. The INCB086550 has been tested in animals but not yet in people. This Study will test different doses of …
Learn More
Intramolecular Imaging with ICG (PRIME)

Intramolecular Imaging with ICG (PRIME)

18 years - 99 years
All genders
Phase 2
Interventional
The purpose of this protocol is to monitor the rate of recurrence in patients who undergo cancer surgery. Patient diagnosed with solid tumor cancers have a high rate of recurrence when surgery is a treatment. The high rates of recurrence suggest that surgeons are unable to completely detect and remove …
Learn More
Fusion - FPX-01-01

Fusion - FPX-01-01

18 years - 99 years
All genders
Phase 1
A first-in-man Phase 1, non-randomized, multi-centre, open-label clinical trial designed to investigate the safety, tolerability, pharmacokinetics of [111In]-FPI-1547 Injection and [225Ac]-FPI-1434 Injection and to establish the maximum tolerated dose of a single [225Ac]-FPI-1434 Injection in patients with solid tumours with demonstrated tumour uptake of [111In]-FPI-1547. Includes a sub-study of FPI-1175 …
Learn More
11 - 20 of 49